GLP-1 and metabolic medicine

Compounded GLP-1

Also called: compounded semaglutide, compounded tirzepatide, research-grade GLP-1

Compounded GLP-1 medications are versions of semaglutide or tirzepatide produced by compounding pharmacies, not the original manufacturers (Novo Nordisk, Eli Lilly). They're cheaper, often sold online or via 'wellness' clinics, and have been used to fill supply gaps. Quality, sterility and dose accuracy vary widely. Multiple deaths and serious injuries have been linked to compounded GLP-1s. UK MHRA does not authorise this route. Avoid.

Why compounded GLP-1 exists

Branded GLP-1s have been in supply shortage since 2022. In the US, FDA rules allow compounding pharmacies to produce alternative versions of drugs on the official shortage list. This created a large grey market for cheaper compounded semaglutide and tirzepatide, often via online clinics with minimal medical oversight. As supply eased in 2025, FDA started restricting compounding again, but the market has not fully shut down.

What goes wrong

  • Active ingredient may not be the same molecule. Some products use semaglutide salts (acetate, sodium) which are not the same as branded sodium salt and have different absorption profiles.
  • Sterility failures: bacterial contamination, fungal contamination.
  • Dose accuracy: compounded vials sometimes contain 50-200 percent of stated dose.
  • Source of active pharmaceutical ingredient: often imported from unregulated suppliers in China or India.
  • No real-world adverse event monitoring.
  • Mixed with B12 or other additives the user is not informed about.

Reported harms

  • FDA: hundreds of adverse event reports involving compounded GLP-1s through 2024-2025.
  • Multiple severe overdoses requiring hospitalisation.
  • Deaths linked to dosing errors and contamination.
  • Bacterial infections at injection sites.
  • Severe gastroparesis disproportionately reported in compounded users.

What about UK availability

  • MHRA does NOT authorise compounded versions of branded medicines for general use.
  • UK pharmacies cannot legally sell compounded semaglutide or tirzepatide as substitutes for Ozempic, Wegovy or Mounjaro.
  • Online sellers offering 'research peptides' or 'unlicensed semaglutide' are operating outside MHRA.
  • Importing compounded GLP-1 from US compounding pharmacies for personal use is technically not legal and not safe.

How to get GLP-1 safely

  1. NHS pathway: ask your GP about referral to specialist Tier 3 weight-management or diabetes services.
  2. Private clinic with MHRA-registered prescribers: typical cost £150-300/month including consultations.
  3. Branded products only: Ozempic, Wegovy, Mounjaro.
  4. Pharmacist-supplied through GP or specialist prescription.
  5. Verify the prescriber is GMC-registered. Verify the pharmacy is GPhC-registered.

Common questions

Is compounded GLP-1 the same drug?
Sometimes the same molecule, sometimes a salt form that behaves differently in the body, sometimes contaminated. Even when it's the same active ingredient, sterility and dose accuracy are unreliable. Cheaper does not mean equivalent.
Why do clinics offer it?
Margin. Branded GLP-1s have low margins for the prescriber. Compounded products are cheap to source and can be marked up substantially. Some clinics frame it as 'access to affordable treatment'; the trade-off is on the patient.
Has anyone died from compounded GLP-1?
FDA has confirmed multiple deaths linked to compounded semaglutide products since 2023. Most involve dosing errors (vials with 5-10x the intended dose) or contamination.
Where can I get cheap GLP-1 legally?
Saxenda (liraglutide) is now available as a generic in some markets at lower cost. NHS access via Tier 3 services is technically free but capacity-limited. Private branded GLP-1 prescriptions in the UK have come down to £150-200/month at competitive online pharmacies. None of these undercut compounded prices, but the safety gap is large.

Sources